GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » Total Liabilities

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Total Liabilities : $6.85 Mil (As of Jun. 2008)


View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals Total Liabilities?

VioQuest Pharmaceuticals's Total Liabilities for the quarter that ended in Jun. 2008 was $6.85 Mil.

VioQuest Pharmaceuticals's quarterly Total Liabilities increased from Dec. 2007 ($5.84 Mil) to Mar. 2008 ($7.38 Mil) but then declined from Mar. 2008 ($7.38 Mil) to Jun. 2008 ($6.85 Mil).

VioQuest Pharmaceuticals's annual Total Liabilities increased from Dec. 2005 ($2.04 Mil) to Dec. 2006 ($2.99 Mil) and increased from Dec. 2006 ($2.99 Mil) to Dec. 2007 ($5.84 Mil).


VioQuest Pharmaceuticals Total Liabilities Historical Data

The historical data trend for VioQuest Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals Total Liabilities Chart

VioQuest Pharmaceuticals Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 1.09 2.04 2.99 5.84

VioQuest Pharmaceuticals Quarterly Data
Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.63 5.59 5.84 7.38 6.85

VioQuest Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

VioQuest Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2007 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.843+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=5.84

Total Liabilities=Total Assets (A: Dec. 2007 )-Total Equity (A: Dec. 2007 )
=1.358--4.484
=5.84

VioQuest Pharmaceuticals's Total Liabilities for the quarter that ended in Jun. 2008 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.694+(0+4.154
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=6.85

Total Liabilities=Total Assets (Q: Jun. 2008 )-Total Equity (Q: Jun. 2008 )
=1.177--5.671
=6.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VioQuest Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 2287, Minneapolis, MN, USA, 55402
Website
VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.
Executives
Mark D Dacko director, officer: CFO and Secretary 800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker officer: V.P. & Chief Financial Officer 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz officer: CFO and Treasurer 65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam director
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli director, officer: Secretary C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf director, officer: President and CEO C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz 10 percent owner WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen director TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines